clinical trial · NCT06285071
Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors
Novo Nordisk A/S·—·enrolling by invitation·n = 23
Haemophilia AHaemophilia BConcizumab
brief summary
The purpose of the study is to investigate the safety and effectiveness of Alhemo® in all participants under real-world clinical practice in Japan. Participants will get Alhemo® as prescribed by the study doctor. The study will last for about 2 years.
started
Aug 8, 2024
primary completion
Apr 30, 2030
completion
Apr 30, 2030
last updated
Jun 15, 2026
official title
A Multi-centre, Open-label, Single-arm, Non-interventional Post-marketing Study to Investigate Safety and Clinical Parameters of Alhemo® Under Routine Clinical Practice in Japan
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol